Active_JJ Surveillance_NN for_IN Scrapie_NP by_IN Third_NP Eyelid_NP Biopsy_NP and_CC Genetic_NP Susceptibility_NP Testing_NP of_IN Flocks_NP of_IN Sheep_NP in_IN Wyoming_NP Control_NP of_IN scrapie_NP ,_, an_DT ovine_JJ transmissible_JJ spongiform_JJ encephalopathy_NN or_CC prion_NN disorder_NN ,_, has_VBZ been_VBN hampered_VBN by_IN the_DT lack_NN of_IN conventional_JJ antemortem_NN diagnostic_JJ tests_NNS ._SENT Currently_RB ,_, scrapie_NN is_VBZ diagnosed_VBN by_IN postmortem_JJ examination_NN of_IN the_DT brain_NN and_CC lymphoid_JJ tissues_NNS for_IN PrPSc_NP ,_, the_DT protein_NN marker_NN for_IN this_DT group_NN of_IN disorders_NNS ._SENT For_IN live_JJ ,_, asymptomatic_JJ sheep_NN ,_, diagnosis_NN using_VBG tonsil_NN or_CC third-eyelid_JJ lymphoid_JJ tissue_NN biopsy_NN and_CC PrPSc_NN assay_NN has_VBZ been_VBN described_VBN ._SENT To_TO evaluate_VB the_DT feasibility_NN and_CC efficacy_NN of_IN third-eyelid_JJ testing_NN for_IN identification_NN of_IN infected_JJ flocks_VBZ and_CC individual_JJ infected_JJ sheep_NN ,_, 690_CD sheep_NN from_IN 22_NP flocks_VBZ were_VBD sampled_VBN by_IN third-eyelid_JJ lymphoid_JJ tissue_NN biopsy_NN and_CC immunohistochemistry_NN ._SENT Sheep_NP were_VBD further_RBR evaluated_VBN for_IN relative_JJ genetic_JJ susceptibility_NN and_CC potential_JJ contact_NN exposure_NN to_TO scrapie_NN ._SENT Third-eyelid_NP testing_NN yielded_VBD suitable_JJ samples_NNS for_IN 80_CD %_NN of_IN the_DT sheep_NN tested_VBD ,_, with_IN a_DT mean_NN of_IN 18.1_CD lymphoid_JJ follicles_NNS (_( germinal_JJ centers_NNS )_) per_IN histologic_JJ section_NN ._SENT Three_CD hundred_CD eleven_NN of_IN the_DT sheep_NN were_VBD sampled_VBN through_IN passive_JJ surveillance_NN programs_NNS ,_, in_IN which_WDT only_JJ sheep_NN with_IN potential_JJ contact_NN with_IN an_DT infected_JJ sheep_NN at_IN a_DT lambing_VBG event_NN were_VBD tested_VBN ,_, regardless_RB of_IN their_PP$ scrapie_NN susceptibility_NN genotype_NN ._SENT In_IN addition_NN ,_, 141_CD genetically_RB susceptible_JJ sheep_NN with_IN no_DT record_NN of_IN contact_NN with_IN an_DT infected_JJ animal_NN at_IN a_DT lambing_VBG event_NN were_VBD sampled_VBN through_IN a_DT targeted_JJ active_JJ surveillance_NN program_NN ._SENT Ten_CD PrPSc-positive_JJ sheep_NN were_VBD identified_VBN through_IN the_DT passive_JJ surveillance_NN program_NN ,_, and_CC an_DT additional_JJ three_CD PrPSc-positive_JJ sheep_NN ,_, including_VBG two_CD from_IN flocks_VBZ with_IN no_DT history_NN of_IN scrapie_NN ,_, were_VBD identified_VBN through_IN the_DT active_JJ surveillance_NN program_NN ._SENT All_DT PrPSc-positive_JJ sheep_NN had_VBD the_DT highly_RB susceptible_JJ PrP_NP genotype_NN ._SENT Third-eyelid_JJ testing_NN is_VBZ a_DT useful_JJ adjunct_NN to_TO flock_VB monitoring_NN programs_NNS ,_, slaughter_NN surveillance_NN ,_, and_CC mandatory_JJ disease_NN reporting_VBG in_IN a_DT comprehensive_JJ scrapie_NN eradication_NN and_CC research_NN program_NN ._SENT Scrapie_NP is_VBZ a_DT fatal_JJ neurologic_JJ disease_NN of_IN sheep_NN and_CC goats_NNS ,_, introduced_VBN into_IN the_DT United_NP States_NPS in_IN 1947_CD and_CC now_RB endemic_JJ in_IN many_JJ states_NNS ._SENT Scrapie_NP is_VBZ a_DT member_NN of_IN the_DT heterogeneous_JJ group_NN of_IN prion_NN diseases_NNS ,_, or_CC transmissible_JJ spongiform_JJ encephalopathies_NNS (_( TSE_NP )_) ,_, which_WDT includes_VBZ bovine_JJ spongiform_JJ encephalopathy_NN (_( BSE_NP )_) ,_, cervid_JJ chronic_JJ wasting_NN disease_NN ,_, and_CC transmissible_JJ mink_NN encephalopathy_NN ._SENT Although_IN scrapie_NN is_VBZ not_RB a_DT zoonotic_JJ disease_NN ,_, the_DT apparent_JJ transmission_NN of_IN BSE_NN to_TO humans_NNS in_IN the_DT United_NP Kingdom_NP has_VBZ resulted_VBN in_IN a_DT call_NN for_IN eradication_NN of_IN all_DT TSE_NP in_IN food-producing_NN animals_NNS ._SENT The_DT transmissible_JJ agent_NN in_IN scrapie_NN remains_VBZ controversial_JJ because_IN no_DT conventional_JJ bacterial_JJ ,_, viral_JJ ,_, fungal_JJ ,_, or_CC toxic_JJ source_NN has_VBZ been_VBN identified_VBN ._SENT The_DT major_JJ component_NN in_IN infectious_JJ tissue_NN homogenates_NNS is_VBZ a_DT relatively_RB denaturation-resistant_JJ conformational_JJ isoform_NN (_( PrPSc_NP )_) of_IN the_DT highly_RB conserved_VBN mammalian_JJ PrP_NP protein_NN (_( PrPC_NP )_) ._SENT The_DT prion_NN model_NN proposes_VBZ that_IN PrPSc_NP and_CC other_JJ less_CC well_RB characterized_VBD cofactors_NNS induce_VB conversion_NN of_IN PrPC_NP to_TO the_DT pathogenic_JJ isoform_NN PrPSc_NN through_IN aggregation_NN and_CC posttranslational_JJ structural_JJ changes_NNS ._SENT Regardless_RB of_IN the_DT etiology_NN of_IN scrapie_NN ,_, PrPSc_NP is_VBZ a_DT reliable_JJ marker_NN for_IN infection_NN ._SENT Scrapie_NN transmission_NN is_VBZ thought_VBN to_TO occur_VB by_IN oral_JJ exposure_NN to_TO the_DT causative_JJ agent_NN ,_, uptake_NN through_IN the_DT intestinal_JJ wall_NN ,_, amplification_NN of_IN the_DT agent_NN in_IN the_DT gut-associated_JJ lymphoid_JJ and_CC nervous_JJ tissue_NN ,_, and_CC transport_VB to_TO the_DT brain_NN through_IN the_DT autonomic_JJ fibers_NNS of_IN the_DT vagus_NN nerve_NN ._SENT In_IN U.S._NP sheep_NN ,_, PrPSc_NP detected_VBD by_IN immunoassay_NN or_CC a_DT transmissible_JJ agent_NN detected_VBN by_IN rodent_NN bioassay_NN is_VBZ found_VBN in_IN some_DT lymphoid_JJ tissue_NN by_IN the_DT age_NN of_IN 14_CD months_NNS and_CC in_IN the_DT brain_NN by_IN 2.5_CD years_NNS ,_, approximately_RB 6_CD months_NNS before_IN onset_NN of_IN clinical_JJ signs_NNS ._SENT Early_JJ accumulation_NN of_IN PrPSc_NP in_IN lymphoid_JJ tissue_NN is_VBZ the_DT basis_NN for_IN preclinical_JJ scrapie_NN diagnosis_NN by_IN immunohistochemistry_NN (_( IHC_NP )_) assay_NN of_IN postmortem_JJ tonsil_NN and_CC antemortem_NN third-eyelid_NN lymphoid_JJ tissue_NN or_CC tonsil_NN biopsy_NN samples_NNS ._SENT Disease_NN transmission_NN depends_VBZ on_IN both_DT exposure_NN to_TO the_DT infectious_JJ agent_NN and_CC susceptible_JJ genetics_NNS in_IN the_DT host_NN ._SENT Sheep_NP housed_VBD with_IN an_DT infected_JJ postparturient_JJ ewe_NN (_( within_IN 60_CD days_NNS of_IN lambing_VBG or_CC abortion_NN )_) are_VBP considered_VBN to_TO be_VB at_IN increased_VBN risk_NN of_IN scrapie_NN ,_, presumably_RB because_IN they_PP are_VBP exposed_VBN to_TO the_DT infectious_JJ agent_NN in_IN placental_JJ and_CC fetal_JJ tissues_NNS or_CC fluids_NNS ._SENT Following_VBG contact_NN with_IN an_DT infected_JJ postparturient_JJ ewe_NN ,_, disease_NN occurs_VBZ almost_RB exclusively_RB in_IN sheep_NN with_IN particular_JJ polymorphisms_NNS in_IN the_DT host_NN PrP_NP gene_NN ._SENT In_IN the_DT U.S._NP sheep_NN population_NN ,_, scrapie_NN (_( whether_IN associated_VBN with_IN clinical_JJ disease_NN or_CC with_IN PrPSc_NP accumulation_NN in_IN the_DT absence_NN of_IN clinical_JJ signs_NNS )_) has_VBZ been_VBN confirmed_VBN only_RB in_IN sheep_NN homozygous_JJ for_IN the_DT PrP_NP allele_NN encoding_VBG glutamine_NN at_IN codon_NN 171_CD (_( QQ171_NP )_) ,_, regardless_RB of_IN breed_NN ._SENT In_IN Europe_NP and_CC the_DT United_NP Kingdom_NP ,_, relative_JJ susceptibility_NN of_IN sheep_NN with_IN several_JJ other_JJ PrP_NP genotypes_NNS is_VBZ reported_VBN in_IN various_JJ breeds_NNS ,_, a_DT finding_VBG useful_JJ in_IN national_JJ scrapie_NN control_NN programs_NNS ._SENT Scrapie_NP is_VBZ typically_RB diagnosed_VBN by_IN IHC_NP assay_NN of_IN brain_NN tissue_NN from_IN sheep_NN with_IN clinical_JJ signs_NNS of_IN scrapie_NN ,_, notably_RB weight_NN loss_NN ,_, wool_NN loss_NN ,_, and_CC ataxia_NN ._SENT Following_VBG diagnosis_NN of_IN an_DT index_NN animal_NN ,_, control_NN measures_NNS in_IN the_DT flock_NN include_VBP culling_VBG or_CC quarantine_NN of_IN sheep_NN at_IN risk_NN due_JJ to_TO susceptible_JJ genetics_NNS and/or_CC possible_JJ contact_NN with_IN the_DT infected_JJ postparturient_JJ ewe_NN ._SENT However_RB ,_, many_JJ infected_JJ sheep_NN die_NN from_IN intercurrent_JJ diseases_NNS or_CC routine_JJ culling_VBG without_IN diagnostic_JJ testing_NN ,_, and_CC identification_NN of_IN infected_JJ flocks_VBZ by_IN surveillance_NN for_IN clinical_JJ scrapie_NN alone_RB may_MD not_RB be_VB sufficient_JJ for_IN disease_NN eradication_NN ._SENT Cooperative_JJ state-federal_JJ programs_NNS that_WDT meet_VBP or_CC exceed_VBP the_DT current_JJ control_NN measures_NNS and_CC that_WDT are_VBP designed_VBN to_TO test_VB or_CC improve_VB program_NN procedures_NNS or_CC facilitate_VBP research_NN are_VBP allowed_VBN as_IN pilot_NN programs_NNS ._SENT The_DT state_NN of_IN Wyoming_NP has_VBZ proposed_VBN a_DT pilot_NN program_NN in_IN which_WDT passive_JJ surveillance_NN (_( quarantine_NN ,_, testing_NN ,_, or_CC removal_NN of_IN sheep_NN having_VBG potential_JJ contact_NN with_IN an_DT infected_JJ ewe_NN )_) is_VBZ supplemented_VBN with_IN active_JJ surveillance_NN ,_, including_VBG live-animal_JJ testing_NN of_IN genetically_RB susceptible_JJ ,_, clinically_RB normal_JJ sheep_NN with_IN no_DT reported_VBN contact_NN with_IN an_DT infected_JJ sheep_NN during_IN a_DT lambing_VBG event_NN ._SENT The_DT objective_NN of_IN this_DT study_NN was_VBD to_TO investigate_VB the_DT feasibility_NN and_CC efficacy_NN of_IN including_VBG third-eyelid_JJ testing_NN and_CC susceptibility_NN genetics_NNS in_IN active_JJ and_CC passive_JJ surveillance_NN programs_NNS ._SENT Study_NN flocks_VBZ ._SENT |_SYM Twenty-two_NP flocks_VBZ in_IN Wyoming_NP were_VBD included_VBN in_IN this_DT study_NN ._SENT Ninety_CD sheep_NN from_IN the_DT University_NP of_IN Wyoming_NP Animal_NP Science_NP Department_NP were_VBD sampled_VBN by_IN third-eyelid_JJ biopsy_NN to_TO estimate_VB the_DT efficiency_NN of_IN eyelid_NN biopsy_NN sampling_NN (_( percentage_NN of_IN sheep_NN with_IN suitable_JJ biopsy_NN samples_NNS )_) for_IN sheep_NN of_IN various_JJ ages_NNS and_CC breeds_NNS ._SENT The_DT sheep_NN were_VBD aged_VBN 14_CD months_NNS to_TO 7_CD years_NNS and_CC represented_VBD four_CD breeds_NNS (_( Suffolk_NP ,_, Columbia_NP ,_, Hampshire_NP ,_, and_CC Rambouillet_NP )_) ._SENT In_IN addition_NN ,_, 600_CD sheep_NN from_IN privately_RB owned_JJ flocks_VBZ in_IN Wyoming_NP were_VBD tested_VBN ._SENT These_DT sheep_NN were_VBD of_IN Suffolk_NP and_CC Hampshire_NP origin_NN ._SENT All_DT sheep_NN over_IN the_DT age_NN of_IN 14_CD months_NNS at_IN the_DT time_NN of_IN testing_NN were_VBD sampled_VBN in_RB flocks_VBZ 1_CD to_TO 5_CD and_CC 7_CD to_TO 13_CD ._SENT Only_JJ sheep_NN over_IN the_DT age_NN of_IN 14_CD months_NNS and_CC considered_VBN at_IN risk_NN due_JJ to_TO potential_JJ contact_NN with_IN a_DT postparturient_JJ ewe_NN subsequently_RB diagnosed_VBN with_IN scrapie_NN (_( see_VB "_`` Relative_JJ risk_NN designation_NN "_'' below_IN )_) were_VBD sampled_VBN in_RB flocks_VBZ 6_CD and_CC 14_CD to_TO 16_CD ._SENT The_DT group_NN designated_VBN flock_NN 16_CD represents_VBZ one_CD sheep_NN with_IN potential_JJ contact_NN risk_NN from_IN each_DT of_IN five_CD flocks_VBZ and_CC two_CD sheep_NN with_IN potential_JJ contact_NN risk_NN from_IN a_DT sixth_JJ flock_NN ._SENT Flocks_VBZ were_VBD included_VBN in_IN the_DT study_NN following_VBG identification_NN of_IN an_DT infected_JJ animal_NN or_CC an_DT animal_NN with_IN potential_JJ contact_NN exposure_NN ,_, either_CC born_VBN into_IN the_DT flock_NN (_( flocks_VBZ 3_CD to_TO 5_CD )_) or_CC purchased_JJ (_( flocks_VBZ 6_CD to_TO 16_CD )_) ._SENT Flocks_VBZ 1_CD and_CC 2_CD were_VBD volunteered_VBN by_IN the_DT producers_NNS for_IN educational_JJ purposes_NNS or_CC due_JJ to_TO industry_NN concerns_NNS about_IN scrapie_NN ._SENT Restraint_NN ._SENT |_SYM One_CD eye_NN on_IN each_DT sheep_NN ,_, usually_RB the_DT left_JJ eye_NN ,_, was_VBD pretreated_VBN with_IN topical_JJ 0.5_CD %_NN sterile_JJ ophthalmic_JJ proparacaine_NN HCl_NP (_( Bausch_NP and_CC Lomb_NP ,_, Tampa_NP ,_, Fla._NP )_) several_JJ minutes_NNS before_IN the_DT procedure_NN was_VBD performed_VBN ._SENT The_DT sheep_NN was_VBD haltered_VBN and_CC restrained_VBN manually_RB ._SENT All_DT sheep_NN were_VBD sampled_VBN on_IN the_DT farm_NN of_IN origin_NN ,_, and_CC equipment_NN for_IN restraint_NN of_IN the_DT sheep_NN varied_VBN among_IN the_DT facilities_NNS ._SENT Many_JJ farms_NNS were_VBD equipped_VBN with_IN a_DT fitting_JJ stand_NN ,_, in_IN which_WDT the_DT head_NN was_VBD immobilized_VBN by_IN resting_VBG the_DT chin_NN on_IN a_DT horizontal_JJ support_NN and_CC securing_VBG a_DT restraint_NN strap_NN behind_IN the_DT head_NN ._SENT Alternative_JJ restraint_NN devices_NNS included_VBD a_DT tilt_NN table_NN in_IN which_WDT the_DT sheep_NN was_VBD restrained_VBN in_IN a_DT squeeze_NN chute_NN ,_, or_CC a_DT head_NN catch_NN in_IN which_WDT partial_JJ restraint_NN was_VBD afforded_VBN by_IN a_DT stanchion_NN ._SENT In_IN all_DT cases_NNS ,_, immobilization_NN of_IN the_DT head_NN was_VBD achieved_VBN through_IN traction_NN on_IN the_DT halter_NN strap_NN ._SENT Optimally_RB ,_, one_CD operator_NN restrained_VBD the_DT sheep_NN 's_POS body_NN ,_, one_CD operator_NN maintained_VBD control_NN of_IN the_DT halter_NN ,_, one_CD person_NN retracted_VBD the_DT third_JJ eyelid_NN ,_, and_CC a_DT fourth_JJ person_NN collected_VBD the_DT biopsy_NN specimen_NN ._SENT If_IN only_RB two_CD operators_NNS were_VBD available_JJ ,_, equipment_NN suitable_JJ for_IN restraint_NN of_IN the_DT sheep_NN was_VBD needed_VBN ;_: one_CD operator_NN maintained_VBD control_NN of_IN the_DT halter_NN and_CC retracted_VBD the_DT third_JJ eyelid_NN ,_, and_CC one_CD operator_NN collected_VBD the_DT sample_NN ._SENT Biopsy_NN sample_NN collection_NN ._SENT |_SYM After_IN adequate_JJ immobilization_NN of_IN the_DT sheep_NN ,_, the_DT third_JJ eyelid_NN was_VBD retracted_VBN by_IN using_VBG 1_CD by_IN 2_CD toothed_JJ forceps_NN (_( Econo_NP Thumb_NP Tissue_NP forceps_NN 21-762_CD ;_: Sklar_NP Instruments_NPS ,_, West_NP Chester_NP ,_, Pa._NP )_) and_CC treated_VBN again_RB with_IN proparacaine_NN ._SENT The_DT lymphoid_JJ tissue_NN was_VBD visualized_VBN on_IN the_DT bulbar_JJ surface_NN as_IN a_DT slightly_RB raised_VBN pink_JJ tissue_NN on_IN either_DT side_NN of_IN the_DT midline_NN (_( Fig._NN ,_, lower_JJR arrow_NN )_) ._SENT The_DT color_NN ,_, location_NN ,_, and_CC size_NN of_IN the_DT tissue_NN varied_VBD slightly_RB among_IN individual_JJ sheep_NN ._SENT Sheep_NP were_VBD sampled_VBN even_RB if_IN there_EX was_VBD no_DT gross_JJ evidence_NN of_IN lymphoid_JJ tissue_NN ._SENT The_DT tissue_NN was_VBD grasped_VBN with_IN a_DT second_JJ set_NN of_IN forceps_NN ,_, raised_VBD slightly_RB from_IN the_DT underlying_VBG connective_JJ tissue_NN ,_, and_CC excised_VBD with_IN single-use_NN curved_VBN Metzenbaum_NP scissors_VBZ (_( Econo_NP Metzenbaum_NP scissors_VBZ 21-336_CD ;_: Sklar_NP Instruments_NPS )_) by_IN using_VBG a_DT medial_NN to_TO lateral_JJ cut_NN ;_: typically_RB ,_, two_CD or_CC three_CD sequential_JJ cuts_NNS with_IN the_DT scissors_NN were_VBD required_VBN to_TO acquire_VB a_DT single_JJ biopsy_NN specimen_NN of_IN sufficient_JJ size_NN containing_VBG the_DT entire_JJ area_NN of_IN lymphoid_JJ tissue_NN on_IN one_CD side_NN of_IN the_DT midline_NN (_( Fig._NN ,_, upper_JJ arrow_NN )_) ._SENT The_DT biopsy_NN sample_NN was_VBD fixed_VBN in_IN 10_CD %_NN neutral_JJ buffered_VBN formalin_NN for_IN at_IN least_JJS 24_CD h._JJ Tissue_NP processing_NN ._SENT |_SYM Typically_RB ,_, fixed_VBN biopsy_NN samples_NNS were_VBD observed_VBN to_TO be_VB folded_VBN in_IN half_NN with_IN the_DT lymphoid_JJ tissue_NN facing_VBG outward_RB ,_, secured_VBN by_IN the_DT indentation_NN formed_VBN by_IN the_DT forceps_NN teeth_NNS ._SENT Biopsy_NN samples_NNS were_VBD opened_VBN using_VBG iris_NN scissors_NN and_CC placed_VBD flat_JJ between_IN biopsy_NN sponges_VBZ in_IN plastic_JJ histopathology_NN cassettes_NNS ._SENT The_DT lymphoid_JJ tissue_NN was_VBD placed_VBN down_RP in_IN the_DT cassettes_NNS ._SENT Cassettes_NNS with_IN properly_RB positioned_VBN biopsy_NN samples_NNS were_VBD immersed_VBN in_IN 95_CD to_TO 98_CD %_NN formic_JJ acid_NN for_IN 1_CD h_NN to_TO decontaminate_VB the_DT tissue_NN ._SENT Samples_NNS were_VBD rinsed_VBN in_IN three_CD changes_NNS of_IN deionized_JJ water_NN and_CC for_IN at_IN least_JJS 10_CD min_NN in_IN running_VBG deionized_JJ water_NN ,_, then_RB reequilibrated_VBN in_IN 10_CD %_NN neutral_JJ buffered_VBN formalin_NN ._SENT Tissues_NNS were_VBD processed_VBN conventionally_RB and_CC embedded_VBN in_IN paraffin_NN ;_: care_NN was_VBD taken_VBN to_TO position_VB the_DT biopsy_NN samples_NNS in_IN the_DT paraffin_NN blocks_VBZ so_RB that_IN the_DT lymphoid_JJ tissue_NN was_VBD facing_VBG and_CC on_IN the_DT same_JJ plane_NN as_IN the_DT surface_NN of_IN the_DT block_NN ,_, to_TO provide_VB the_DT largest_JJS possible_JJ section_NN when_WRB cut_VBN ._SENT Adhesion_NN of_IN formic_JJ acid-decontaminated_JJ tissue_NN to_TO glass_NN slides_NNS required_VBD additional_JJ attention_NN during_IN preparation_NN ._SENT Three-_NNS to_TO five-micrometer-thick_JJ sections_NNS were_VBD cut_VBN with_IN a_DT microtome_NN and_CC applied_VBN to_TO adhesive-coated_JJ aminosilane-treated_JJ slides_NNS (_( Newcomer_NP Supply_NP ,_, Middleton_NP ,_, Wis._NP )_) ._SENT Residual_JJ moisture_NN under_IN the_DT section_NN was_VBD removed_VBN with_IN absorbent_JJ laboratory_NN tissue_NN paper_NN ,_, and_CC slides_NNS were_VBD positioned_VBN vertically_RB to_TO dry_VB for_IN at_IN least_JJS 1_CD h._JJ Slides_NNS were_VBD baked_VBN at_IN 57C_NN for_IN approximately_RB 15_CD h_NN (_( overnight_JJ )_) to_TO remove_VB excess_JJ paraffin_NN ._SENT Immunostaining_NP ._SENT |_SYM Sections_NPS were_VBD rehydrated_VBN through_IN xylene_NN substitutes_NNS and_CC graded_VBN alcohols_NNS ,_, then_RB treated_VBN with_IN 95_CD %_NN formic_JJ acid_NN for_IN 5_CD min_NN and_CC neutralized_VBN by_IN three_CD changes_NNS of_IN 0.1_CD M_NP Tris-HCl_NP ,_, pH_NN 7.6_CD ._SENT Antigen_NN retrieval_NN was_VBD performed_VBN by_IN incubation_NN at_IN 120C_NP in_IN a_DT medical_JJ pressure_NN cooker_NN (_( BioCare_NP Medical_NP ,_, Walnut_NP Creek_NP ,_, Calif._NP )_) for_IN 20_CD min_NN in_IN a_DT modified_JJ citrate_NN buffer_NN (_( Target_NP Retrieval_NP solution_NN ,_, pH_NN 6.1_CD ;_: Dako_NP Corporation_NP ,_, Carpinteria_NP ,_, Calif._NP )_) ._SENT IHC_NP was_VBD performed_VBN on_IN an_DT automated_JJ immunostainer_NN (_( NexES_NP ;_: Ventana_NP Medical_NP Systems_NP ,_, Tucson_NP ,_, Ariz._NP )_) by_IN using_VBG the_DT manufacturer_NN 's_POS detection_NN reagents_NNS (_( antibody_NN diluent_NN ,_, AEC_NP detection_NN kit_NN ,_, hematoxylin_NN ,_, bluing_NN ,_, and_CC mouse_NN immunoglobulin_NN G1_NP [_SYM IgG1_NP ]_SYM negative_JJ control_NN antibody_NN )_) ._SENT The_DT primary_JJ antibody_NN was_VBD a_DT cocktail_NN of_IN two_CD monoclonal_NN antibodies_NNS (_( MAbs_NP )_) to_TO separate_JJ epitopes_NNS on_IN the_DT PrP_NP molecule_NN (_( MAb_NP F99/97.6.1_NP and_CC MAb_NP F89/160.1.5_NP ;_: Veterinary_NP Medical_NP Research_NP Development_NP ,_, Inc._NP ,_, Pullman_NP ,_, Wash._NP )_) at_IN 5_CD mug/ml_NN each_DT in_IN antibody_NN diluent_NN (_( Ventana_NP Medical_NP Systems_NP )_) filtered_VBD through_IN a_DT 0.22-mum-pore-size_JJ syringe_NN top_JJ filter_NN ._SENT The_DT primary_JJ antibody_NN was_VBD applied_VBN for_IN the_DT maximum_JJ time_NN available_JJ with_IN the_DT automated_JJ system_NN (_( 32_CD min_NN )_) ,_, followed_VBN by_IN biotinylated_JJ goat_NN anti-mouse_NN IgG_NP ,_, streptavidin-conjugated_JJ horseradish_NN peroxidase_NN ,_, and_CC 3-amino-9-ethylcarbazole_JJ as_IN a_DT chromogen_NN ._SENT The_DT default_NN settings_NNS for_IN incubation_NN time_NN and_CC temperature_NN provided_VBN by_IN the_DT manufacturer_NN were_VBD used_VBN for_IN all_DT detection_NN steps_NNS ._SENT The_DT slides_NNS were_VBD counterstained_VBN with_IN hematoxylin_NN ,_, rinsed_VBD ,_, and_CC covered_VBN with_IN coverslips_NNS by_IN use_NN of_IN a_DT compatible_JJ mounting_VBG medium_NN (_( Faramount_NP aqueous_JJ mounting_VBG medium_NN ;_: Dako_NP )_) ._SENT Lymphoid_JJ tissue_NN (_( tonsil_NN or_CC retropharyngeal_JJ lymph_NN node_NN )_) from_IN an_DT infected_JJ sheep_NN was_VBD used_VBN as_IN a_DT positive_JJ control_NN ._SENT Negative_JJ controls_NNS included_VBD replacement_NN of_IN the_DT primary_JJ anti-PrP_NP antibodies_NNS with_IN an_DT isotype_NN control_NN antibody_NN (_( Ventana_NP )_) and_CC assay_NN of_IN tissues_NNS from_IN uninfected_JJ sheep_NN ._SENT Lymphoid_JJ follicles_NNS appearing_VBG as_IN discrete_JJ oval_NN or_CC round_NN areas_NNS with_IN a_DT darker_JJR border_NN were_VBD counted_VBN on_IN each_DT section_NN ._SENT Sections_NNS were_VBD considered_VBN "_`` PrPSc_NP detected_VBD "_`` if_IN a_DT granular_JJ red_JJ precipitate_NN was_VBD noted_VBN in_IN lymphoid_JJ follicles_NNS (_( germinal_JJ centers_NNS )_) ,_, regardless_RB of_IN the_DT number_NN of_IN follicles_NNS in_IN the_DT section_NN ._SENT Sections_NNS were_VBD considered_VBN "_`` no_DT PrPSc_NP detected_VBD "_`` if_IN no_DT precipitate_NN was_VBD noted_VBN in_IN a_DT section_NN ._SENT A_DT minimum_NN of_IN six_CD lymphoid_JJ follicles_NNS per_IN section_NN were_VBD needed_VBN for_IN this_DT designation_NN ._SENT Sections_NNS with_IN no_DT immunostaining_NN and_CC fewer_JJR than_IN six_CD lymphoid_JJ follicles_NNS were_VBD scored_VBN "_`` insufficient_JJ lymphoid_JJ tissue_NN for_IN determination_NN ._SENT "_`` All_DT IHC_NP assays_NNS were_VBD scored_VBN by_IN trained_JJ observers_NNS with_IN no_DT knowledge_NN of_IN the_DT potential_JJ contact_NN or_CC genetic_JJ susceptibility_NN status_NN of_IN the_DT sheep_NN ._SENT Relative_JJ risk_NN designation_NN ._SENT |_SYM Sheep_NP were_VBD scored_VBN for_IN potential_JJ contact_NN risk_NN by_IN using_VBG producer_NN records_NNS and_CC the_DT definitions_NNS established_VBN in_IN the_DT Code_NP of_IN Federal_NP Regulations_NPS 79.4_NP ._SENT Briefly_RB ,_, sheep_NN were_VBD defined_VBN as_IN high_JJ risk_NN by_IN potential_JJ contact_NN if_IN they_PP were_VBD born_VBN in_IN a_DT flock_NN during_IN the_DT same_JJ lambing_VBG season_NN as_IN a_DT lambing_VBG event_NN by_IN a_DT sheep_NN subsequently_RB diagnosed_VBN with_IN scrapie_NN ._SENT Lambing_NP events_NNS include_VBP the_DT birth_NN of_IN an_DT infected_JJ sheep_NN as_RB well_RB as_IN parturition_NN or_CC abortion_NN by_IN an_DT infected_JJ ewe_NN in_IN any_DT year_NN of_IN her_PP$ life_NN ._SENT Sheep_NP were_VBD considered_VBN to_TO be_VB at_IN lower_JJR risk_NN by_IN contact_NN if_IN they_PP were_VBD born_VBN on_IN the_DT farm_NN at_IN other_JJ times_NNS ,_, in_IN different_JJ lambing_VBG facilities_NNS on_IN the_DT same_JJ farm_NN ,_, or_CC on_IN farms_NNS without_IN reported_VBN cases_NNS of_IN scrapie_NN ._SENT If_IN an_DT infected_JJ ewe_NN had_VBD produced_VBN at_IN least_JJS one_CD lamb_NN at_IN the_DT facility_NN and_CC no_DT birth_NN records_NNS were_VBD available_JJ for_IN the_DT flock_NN ,_, all_DT sheep_NN born_VBN in_IN the_DT flock_NN during_IN the_DT years_NNS that_IN the_DT infected_JJ ewe_NN lambed_VBN or_CC aborted_VBN were_VBD designated_VBN high_JJ risk_NN ._SENT Relative_JJ contact_NN risk_NN status_NN was_VBD based_VBN on_IN producer_NN records_NNS ,_, and_CC no_DT outside_JJ measure_NN of_IN the_DT accuracy_NN of_IN those_DT records_NNS is_VBZ available_JJ ._SENT No_DT producer_NN could_MD rule_VB out_RP a_DT previously_RB undetected_JJ scrapie_NN case_NN ,_, because_IN some_DT of_IN the_DT clinical_JJ signs_NNS (_( particularly_RB weight_NN loss_NN )_) occur_VBP frequently_RB in_IN these_DT flocks_VBZ and_CC result_NN in_IN culling_VBG of_IN the_DT animal_NN without_IN diagnostic_JJ testing_NN ._SENT Sheep_NP were_VBD scored_VBN for_IN relative_JJ genetic_JJ susceptibility_NN based_VBN on_IN the_DT deduced_VBN amino_NN acid_NN sequence_NN at_IN residue_NN 171_CD ._SENT Blood_NN was_VBD collected_VBN by_IN jugular_JJ venipuncture_NN into_IN EDTA-treated_JJ vacuum_NN tubes_NNS and_CC shipped_VBN to_TO a_DT commercial_JJ laboratory_NN for_IN scrapie_NN susceptibility_NN testing_NN (_( GeneCheck_NP ,_, Fort_NP Collins_NP ,_, Colo._NP )_) ._SENT DNA_NP was_VBD extracted_VBN from_IN the_DT buffy_JJ coat_NN ,_, amplified_VBN by_IN PCR_NP ,_, and_CC analyzed_VBD by_IN a_DT DNA_NP mismatch_NN binding_VBG assay_NN ._SENT The_DT diploid_JJ genotype_NN was_VBD reported_VBN as_IN QQ_NP ,_, QR_NP ,_, or_CC RR_NP ._SENT However_RB ,_, this_DT assay_NN does_VBZ not_RB distinguish_VB between_IN sequences_NNS encoding_VBG glutamine_NN (_( Q_NP )_) and_CC sequences_NNS encoding_VBG histidine_NN (_( H_NP )_) (_( both_CC are_VBP reported_VBN as_IN 171Q_NP )_) ,_, and_CC samples_NNS scored_VBD QQ_NP may_MD actually_RB be_VB QQ_NP ,_, QH_NP ,_, or_CC HH_NP ._SENT Samples_NNS scored_VBD QR_NP may_MD be_VB QR_NP or_CC HR_NP ._SENT Samples_NNS scored_VBD RR_NP are_VBP unequivocally_RB homozygous_JJ for_IN arginine_NN (_( R_NN )_) at_IN position_NN 171_CD ._SENT Sheep_NP were_VBD considered_VBN to_TO have_VB high_JJ genetic_JJ susceptibility_NN if_IN their_PP$ genotype_NN was_VBD 171QQ_JJ ,_, 171QH_NP ,_, or_CC 171HH_NP and_CC to_TO have_VB lower_JJR genetic_JJ susceptibility_NN if_IN their_PP$ genotype_NN was_VBD 171QR_NP ,_, 171HR_NP ,_, or_CC 171RR_NP ._SENT Surveillance_NN programs_NNS ._SENT |_SYM Under_IN the_DT current_JJ program_NN ,_, passive_JJ surveillance_NN includes_VBZ testing_NN of_IN all_DT sheep_NN in_IN flocks_VBZ in_IN which_WDT an_DT infected_JJ animal_NN was_VBD born_VBN or_CC produced_VBN a_DT lamb_NN and_CC all_DT sheep_NN sold_VBN from_IN those_DT flocks_VBZ if_IN they_PP were_VBD born_VBN in_IN a_DT year_NN in_IN which_WDT the_DT infected_JJ ewe_NN produced_VBD a_DT lamb_NN ._SENT The_DT passive_JJ surveillance_NN program_NN therefore_RB includes_VBZ sheep_NN with_IN potential_JJ contact_NN with_IN the_DT transmissible_JJ agent_NN shed_VBN at_IN parturition_NN ,_, even_RB if_IN those_DT sheep_NN are_VBP at_IN low_JJ genetic_JJ risk_NN ._SENT Active_JJ surveillance_NN includes_VBZ only_RB genetically_RB susceptible_JJ sheep_NN with_IN no_DT reported_VBN contact_NN risk_NN ._SENT In_IN some_DT flocks_VBZ ,_, all_DT sheep_NN over_IN the_DT age_NN of_IN 14_CD months_NNS were_VBD sampled_VBN ,_, even_RB if_IN they_PP were_VBD not_RB eligible_JJ for_IN either_DT program_NN ._SENT The_DT number_NN of_IN sheep_NN sampled_VBN in_IN each_DT surveillance_NN program_NN (_( or_CC sampled_VBN as_IN whole-flock_NN testing_NN but_CC enrolled_VBN in_IN neither_DT program_NN )_) is_VBZ shown_VBN in_IN Table_NP ._SENT FIG._NN 1_CD ._SENT |_SYM Bulbar_NP surface_NN ,_, nictitating_VBG membrane_NN of_IN a_DT Suffolk_NP sheep_NN ._SENT Bulbar_JJ surface_NN ,_, nictitating_VBG membrane_NN of_IN a_DT Suffolk_NP sheep_NN ._SENT The_DT lymphoid_JJ tissue_NN is_VBZ typically_RB visualized_VBN as_IN a_DT slightly_RB raised_VBN ,_, red_JJ to_TO pink_JJ area_NN (_( lower_JJR arrow_NN )_) ._SENT Complete_JJ excision_NN of_IN the_DT lymphoid_JJ tissue_NN (_( upper_JJ arrow_NN )_) is_VBZ visible_JJ approximately_RB 2_CD months_NNS after_IN biopsy_NN ._SENT The_DT lymphoid_JJ tissue_NN at_IN this_DT site_NN does_VBZ not_RB regenerate_VB ._SENT FIG._NN 2_CD ._SENT |_SYM IHC_NP detection_NN of_IN PrPSc_NP in_IN the_DT nictitating_VBG membrane_NN lymphoid_JJ tissue_NN ._SENT IHC_NP detection_NN of_IN PrPSc_NP in_IN the_DT nictitating_VBG membrane_NN lymphoid_JJ tissue_NN ._SENT A_DT third-eyelid_JJ biopsy_NN specimen_NN from_IN a_DT live_JJ sheep_NN with_IN preclinical_JJ scrapie_NN is_VBZ shown_VBN ._SENT Lymphoid_JJ follicles_NNS (_( discrete_JJ round_NN to_TO oval_JJ accumulations_NNS of_IN lymphocytes_NNS ,_, macrophages_NNS ,_, and_CC dendritic_JJ cells_NNS with_IN a_DT dark_JJ border_NN )_) show_VBP granular_JJ PrPSc_NP immunoreactivity_NN (_( red_JJ )_) when_WRB immunostained_JJ with_IN a_DT cocktail_NN of_IN MAbs_NP F89/160.1_NP ._SENT and_CC F99/97.6.1_NP ._SENT Bar_NP ,_, 200_CD mum_NN ._SENT TABLE_NN 1_CD |_SYM Suitability_NN of_IN eyelid_NN biopsy_NN samples_NNS from_IN sheep_NN of_IN four_CD breeds_NNS ,_, aged_VBD 1_CD to_TO 7_CD years_NNS TABLE_NP 2_CD |_SYM Flocks_NP and_CC sheep_NN sampled_VBN by_IN third-eyelid_JJ biopsy_NN and_CC PrP_NP genotyping_JJ Third-eyelid_NP biopsy_NN samples_NNS were_VBD collected_VBN from_IN a_DT university-owned_JJ flock_NN to_TO determine_VB if_IN particular_JJ breeds_NNS of_IN sheep_NN or_CC age_NN groups_NNS were_VBD unsuitable_JJ for_IN this_DT procedure_NN ._SENT Ninety_CD sheep_NN of_IN four_CD breeds_NNS were_VBD available_JJ for_IN sampling_NN ._SENT Suitable_JJ samples_NNS were_VBD those_DT with_IN at_IN least_JJS six_CD lymphoid_JJ follicles_NNS per_IN section_NN ._SENT Nine_CD sheep_NN were_VBD sampled_VBN twice_RB because_IN the_DT left_JJ eye_NN did_VBD not_RB appear_VB to_TO have_VB adequate_JJ lymphoid_JJ tissue_NN when_WRB examined_VBN grossly_RB ._SENT Five_CD of_IN these_DT nine_CD animals_NNS had_VBD suitable_JJ biopsy_NN specimens_NNS from_IN both_DT eyes_NNS ._SENT One_CD animal_NN ,_, a_DT 5-year-old_JJ Columbia_NP ,_, had_VBD unsuitable_JJ samples_NNS from_IN both_DT eyelids_NNS ._SENT Three_CD animals_NNS had_VBD one_CD suitable_JJ sample_NN and_CC one_CD unsuitable_JJ sample_NN ;_: this_DT group_NN included_VBD a_DT 3-year-old_JJ Hampshire_NP ,_, a_DT 4-year-old_JJ Columbia_NP ,_, and_CC a_DT 2-year-old_JJ Suffolk_NP ._SENT The_DT overall_JJ efficiency_NN of_IN testing_NN was_VBD 76_CD %_NN (_( 68_CD of_IN 90_CD )_) when_WRB the_DT results_NNS from_IN either_DT eyelid_NN were_VBD used_VBN to_TO score_VB an_DT individual_JJ sheep_NN ._SENT There_EX was_VBD no_DT breed_NN for_IN which_WDT all_DT samples_NNS were_VBD unsuitable_JJ ._SENT There_EX was_VBD a_DT trend_NN toward_IN a_DT lower_JJR percentage_NN of_IN suitable_JJ samples_NNS from_IN sheep_NN older_JJR than_IN 3_CD years_NNS ,_, but_CC a_DT larger_JJR study_NN population_NN is_VBZ needed_VBN before_IN conclusions_NNS on_IN the_DT feasibility_NN of_IN testing_VBG older_JJR sheep_NN can_MD be_VB drawn_VBN ._SENT A_DT total_NN of_IN 600_CD sheep_NN from_IN 21_CD producer-owned_NP flocks_VBZ were_VBD assessed_VBN for_IN evidence_NN of_IN infection_NN with_IN the_DT scrapie_NN agent_NN by_IN IHC_NP of_IN third-eyelid_JJ biopsy_NN samples_NNS and_CC for_IN relative_JJ genetic_JJ susceptibility_NN to_TO scrapie_NN by_IN DNA_NN genotyping_NN ._SENT Sampled_VBN sheep_NN were_VBD over_IN the_DT age_NN of_IN 14_CD months_NNS and_CC were_VBD primarily_RB of_IN the_DT Suffolk_NP or_CC Hampshire_NP breed_NN ._SENT Sheep_NP were_VBD housed_VBN in_RB flocks_VBZ with_IN no_DT reported_VBN cases_NNS of_IN scrapie_NN ,_, flocks_VBZ in_IN which_WDT an_DT infected_JJ ewe_NN was_VBD born_VBN or_CC had_VBD produced_VBN at_IN least_JJS one_CD lamb_NN ,_, and_CC flocks_VBZ with_IN at_IN least_JJS one_CD purchased_JJ animal_NN with_IN potential_JJ contact_NN exposure_NN in_IN the_DT flock_NN of_IN origin_NN ._SENT The_DT PrP_NP genotypic_JJ ratio_NN in_IN this_DT sample_NN was_VBD 0.48:0.52_CD (_( 290_CD sheep_NN with_IN the_DT highly_RB susceptible_JJ 171QQ_NP ,_, -QH_NN ,_, or_CC -HH_NN genotype_NN and_CC 310_CD sheep_NN with_IN the_DT lower-susceptibility_NN 171QR_NN ,_, -RH_NN ,_, or_CC -RR_NP genotype_NN )_) ._SENT This_DT ratio_NN is_VBZ not_RB significantly_RB different_JJ from_IN that_WDT reported_VBD for_IN an_DT independent_JJ sample_NN of_IN 1,000_CD U.S._NP Suffolk_NP sheep_NN in_IN 1996_CD ._SENT Three_CD hundred_CD eleven_NN of_IN the_DT 600_CD sheep_NN in_IN the_DT study_NN were_VBD tested_VBN under_IN passive_JJ surveillance_NN programs_NNS ,_, representing_VBG sheep_NN with_IN potential_JJ contact_NN risk_NN from_IN exposure_NN to_TO an_DT infected_JJ ewe_NN at_IN parturition_NN ._SENT Eighty-five_JJ of_IN 311_CD had_VBD the_DT highly_RB susceptible_JJ genotype_NN ._SENT One_CD hundred_CD forty-one_NN of_IN the_DT 600_CD sheep_NN were_VBD tested_VBN under_IN the_DT Wyoming_NP active_JJ surveillance_NN program_NN and_CC represent_VB genetically_RB susceptible_JJ sheep_NN with_IN no_DT record_NN of_IN contact_NN with_IN an_DT infected_JJ sheep_NN at_IN a_DT lambing_VBG event_NN ,_, whether_IN they_PP resided_VBD in_RB flocks_VBZ with_IN a_DT purchased_VBN animal_NN with_IN potential_JJ contact_NN risk_NN at_IN a_DT different_JJ facility_NN (_( n_NN =_SYM 96_CD )_) or_CC in_RB flocks_VBZ with_IN no_DT history_NN of_IN scrapie_NN contact_NN in_IN either_DT native_JJ or_CC purchased_VBN animals_NNS (_( n_NN =_SYM 45_CD )_) ._SENT One_CD hundred_CD forty-eight_NN sheep_NN in_IN the_DT lower-genetic-susceptibility_NN group_NN and_CC with_IN no_DT reported_VBN contact_NN with_IN an_DT infected_JJ postparturient_JJ ewe_NN were_VBD tested_VBN because_IN they_PP were_VBD housed_VBN with_IN sheep_NN in_IN the_DT active_JJ surveillance_NN trial_NN ._SENT Sheep_NP were_VBD tested_VBN for_IN PrPSc_NP ,_, a_DT marker_NN for_IN scrapie_NN ,_, by_IN third-eyelid_JJ lymphoid_JJ tissue_NN biopsy_NN and_CC IHC_NP analysis_NN ._SENT Biopsy_NN samples_NNS of_IN the_DT third_JJ eyelid_NN from_IN 481_CD (_( 80_CD %_NN )_) of_IN the_DT sheep_NN tested_VBD contained_VBN at_IN least_JJS six_CD lymphoid_JJ follicles_NNS and_CC were_VBD considered_VBN suitable_JJ for_IN diagnosis_NN ,_, although_IN all_DT biopsy_NN samples_NNS were_VBD analyzed_VBN by_IN IHC_NP ._SENT The_DT mean_JJ follicle_NN count_NN in_IN suitable_JJ biopsy_NN samples_NNS was_VBD 18.1_CD (_( standard_NN deviation_NN ,_, 13.3_CD )_) ._SENT PrPSc_NP was_VBD detected_VBN in_IN 13_CD of_IN the_DT biopsy_NN samples_NNS ,_, collected_VBN from_IN sheep_NN on_IN seven_CD farms_NNS ._SENT All_DT 13_CD sheep_NN with_IN PrPSc_NP detected_VBD in_IN lymphoid_JJ tissue_NN had_VBD the_DT highly_RB susceptible_JJ PrP_NP 171_CD genotype_NN QQ_NP ,_, QH_NP ,_, or_CC HH_NP ._SENT Of_IN the_DT 13_CD sheep_NN with_IN positive_JJ eyelid_NN biopsy_NN samples_NNS ,_, 4_CD were_VBD removed_VBN for_IN immediate_JJ necropsy_NN ,_, and_CC scrapie_NN was_VBD confirmed_VBN by_IN IHC_NP of_IN brain_NN and/or_CC lymphoid_JJ tissues_NNS ._SENT Nine_CD sheep_NN were_VBD moved_VBN to_TO quarantine_VB ._SENT Scrapie_NP has_VBZ been_VBN confirmed_VBN in_IN seven_CD of_IN these_DT nine_CD sheep_NN by_IN postmortem_JJ analysis_NN following_VBG development_NN of_IN clinical_JJ signs_NNS and_CC in_IN one_CD of_IN these_DT nine_CD sheep_NN following_VBG acute_JJ loss_NN (_( found_VBN dead_RB with_IN no_DT clinical_JJ signs_NNS )_) ._SENT The_DT last_JJ of_IN the_DT nine_CD sheep_NN brought_VBN to_TO quarantine_VB is_VBZ asymptomatic_JJ at_IN the_DT age_NN of_IN approximately_RB 36_CD months_NNS ._SENT Ten_CD of_IN the_DT 13_CD PrPSc-positive_JJ sheep_NN were_VBD identified_VBN by_IN the_DT passive_JJ surveillance_NN program_NN ,_, and_CC 3_CD were_VBD identified_VBN by_IN the_DT active_JJ surveillance_NN program_NN ._SENT The_DT positive_JJ samples_NNS were_VBD collected_VBN from_IN sheep_NN in_IN flocks_VBZ in_IN which_WDT an_DT infected_JJ sheep_NN had_VBD been_VBN born_VBN (_( n_NN =_SYM 7_CD )_) ,_, flocks_VBZ with_IN no_DT reported_VBN cases_NNS of_IN scrapie_NN (_( n_NN =_SYM 2_CD )_) ,_, and_CC flocks_VBZ with_IN at_IN least_JJS one_CD sheep_NN purchased_VBN from_IN an_DT infected_JJ flock_NN (_( n_NN =_SYM 4_CD )_) ,_, although_IN in_IN one_CD case_NN ,_, the_DT PrPSc-positive_JJ sheep_NN was_VBD not_RB the_DT purchased_VBN sheep_NN with_IN contact_NN risk_NN but_CC an_DT unrelated_JJ animal_NN purchased_VBN from_IN a_DT different_JJ flock_NN ._SENT The_DT efficiency_NN of_IN the_DT surveillance_NN programs_NNS was_VBD estimated_VBN as_IN the_DT number_NN of_IN PrPSc-positive_JJ sheep_NN per_IN number_NN of_IN sheep_NN in_IN each_DT program_NN (_( 10_CD of_IN 311_CD ,_, or_CC 3.2_CD %_NN ,_, in_IN the_DT passive_JJ surveillance_NN program_NN and_CC 3_CD of_IN 141_CD ,_, or_CC 2.1_CD %_NN ,_, in_IN the_DT active_JJ surveillance_NN program_NN )_) ._SENT TABLE_NN 3_CD |_SYM Flock_NP status_NN at_IN the_DT time_NN of_IN testing_NN and_CC risk_NN status_NN of_IN PrPSc-positive_JJ sheep_NN Scrapie_NP was_VBD reported_VBN as_IN a_DT clinical_JJ entity_NN nearly_RB 300_CD years_NNS ago_RB and_CC was_VBD introduced_VBN into_IN the_DT United_NP States_NPS in_IN 1947_CD ._SENT In_IN the_DT United_NP States_NP ,_, control_NN programs_NNS have_VBP relied_VBN on_IN total_JJ or_CC partial_JJ flock_NN depopulation_NN following_VBG diagnosis_NN of_IN the_DT disease_NN in_IN a_DT sheep_NN with_IN clinical_JJ signs_NNS of_IN scrapie_NN ._SENT The_DT insidious_JJ nature_NN of_IN the_DT disease_NN ,_, the_DT long_JJ preclinical_JJ incubation_NN period_NN ,_, the_DT lack_NN of_IN a_DT preclinical_JJ test_NN ,_, loss_NN of_IN infected_JJ sheep_NN from_IN intercurrent_JJ disease_NN before_IN development_NN of_IN clinical_JJ signs_NNS ,_, and_CC underreporting_VBG of_IN scrapie_NN due_JJ to_TO the_DT negative_JJ economic_JJ effect_NN of_IN a_DT diagnosis_NN have_VBP contributed_VBN to_TO the_DT failure_NN of_IN these_DT programs_NNS to_TO control_VB the_DT prevalence_NN of_IN scrapie_NN ,_, which_WDT is_VBZ estimated_VBN at_IN 0.07_CD %_NN in_IN the_DT United_NP States_NPS (_( based_VBN on_IN a_DT mailed_VBN producer_NN survey_NN conducted_VBN in_IN 1996_CD by_IN the_DT National_NP Animal_NP Health_NP Monitoring_NP System_NP of_IN the_DT U.S._NP Department_NP of_IN Agriculture_NP (_( USDA_NP )_) Animal_NP and_CC Plant_NP Health_NP Inspection_NP Service_NP )_) ._SENT State_NN and_CC federal_JJ flock_NN certification_NN programs_NNS ,_, in_IN which_WDT producers_NNS of_IN monitored_VBN flocks_VBZ agree_VB to_TO purchase_VB breeding_VBG stock_NN from_IN similarly_RB monitored_JJ flocks_VBZ ,_, permanent_JJ identification_NN of_IN individual_JJ sheep_NN and/or_CC flock_NN of_IN origin_NN ,_, and_CC restrictions_NNS on_IN interstate_JJ movement_NN of_IN suspect_JJ and_CC high-risk_JJ animals_NNS have_VBP been_VBN in_IN place_NN since_IN 1992_CD ._SENT The_DT USDA_NP Animal_NP and_CC Plant_NP Health_NP Inspection_NP Service_NP recently_RB expanded_VBD the_DT program_NN to_TO include_VB identification_NN of_IN breeding_NN and_CC mature_JJ sheep_NN and_CC breeding_VBG goats_NNS in_IN interstate_JJ commerce_NN ,_, uniform_JJ standards_NNS for_IN state_NN scrapie_NN control_NN programs_NNS ,_, indemnity_NN payments_NNS ,_, slaughter_NN surveillance_NN ,_, and_CC third-eyelid_JJ testing_NN of_IN exposed_JJ animals_NNS and/or_CC flocks_VBZ ._SENT These_DT programs_NNS are_VBP being_VBG implemented_VBN to_TO eradicate_VB scrapie_NN from_IN the_DT United_NP States_NPS ._SENT The_DT development_NN of_IN the_DT third-eyelid_JJ test_NN for_IN antemortem_NN diagnosis_NN of_IN scrapie_NN and_CC the_DT identification_NN of_IN PrP_NP genotypes_NNS associated_VBN with_IN clinical_JJ and_CC subclinical_JJ PrPSc_NP accumulation_NN have_VBP provided_VBN additional_JJ means_NNS for_IN controlling_VBG scrapie_NN in_IN the_DT U.S._NP sheep_NN population_NN ._SENT The_DT estimated_JJ specificity_NN of_IN the_DT third-eyelid_JJ test_NN approaches_VBZ 100_CD %_NN ._SENT The_DT estimated_JJ sensitivity_NN of_IN the_DT test_NN is_VBZ 85_CD to_TO 90_CD %_NN ._SENT The_DT false-negative_JJ results_NNS are_VBP due_JJ to_TO a_DT number_NN of_IN factors_NNS ._SENT Some_DT infected_JJ sheep_NN have_VBP PrPSc_NN detectable_JJ in_IN the_DT brain_NN but_CC not_RB in_IN lymphoid_JJ tissues_NNS ;_: in_IN other_JJ cases_NNS ,_, PrPSc_NP is_VBZ detectable_JJ in_IN tonsil_NN but_CC not_RB in_IN antemortem_NN eyelid_NN biopsy_NN specimens_NNS ,_, due_JJ in_IN part_NN to_TO inadequate_JJ biopsy_NN sample_NN size_NN ._SENT Optimal_JJ sampling_NN conditions_NNS include_VBP a_DT restraint_NN device_NN such_JJ as_IN a_DT tilt_NN table_NN ,_, fitting_JJ stand_NN ,_, or_CC head_NN catch_NN and_CC adequately_RB trained_VBN personnel_NNS for_IN immobilization_NN of_IN the_DT head_NN ,_, retraction_NN of_IN the_DT eyelid_NN ,_, and_CC biopsy_NN sample_NN collection_NN ._SENT Laboratory_NN handling_NN of_IN the_DT tissue_NN to_TO maximize_VB the_DT number_NN of_IN follicles_NNS available_JJ for_IN inspection_NN in_IN a_DT single_JJ histologic_JJ section_NN requires_VBZ laboratory_NN personnel_NNS trained_VBN in_IN recognizing_VBG the_DT lymphoid_JJ side_NN of_IN the_DT tissue_NN and_CC embedding_VBG a_DT flat_JJ sample_NN in_IN the_DT plane_NN of_IN the_DT microtome_NN cut_NN ._SENT In_IN other_JJ trials_NNS ,_, techniques_NNS such_JJ as_IN embedding_VBG strips_NNS of_IN lymphoid_JJ tissue_NN at_IN right_JJ angles_NNS to_TO the_DT plane_NN of_IN the_DT microtome_NN cut_NN or_CC embedding_VBG folded_VBN or_CC rolled_VBN tissues_NNS typically_RB resulted_VBD in_IN small_JJ numbers_NNS of_IN follicles_NNS available_JJ for_IN inspection_NN in_IN each_DT section_NN ._SENT In_IN the_DT present_JJ study_NN ,_, sampling_NN was_VBD performed_VBN by_IN one_CD of_IN three_CD veterinarians_NNS (_( J.V.D._NP ,_, J.R.L._NP ,_, and_CC E.S.W._NP )_) ,_, and_CC IHC_NP of_IN samples_NNS from_IN producer_NN flocks_VBZ was_VBD performed_VBN by_IN one_CD person_NN (_( A.K.A._NP )_) ._SENT When_WRB sampling_NN ,_, tissue_NN handling_NN ,_, and_CC assay_NN were_VBD performed_VBN under_IN these_DT circumstances_NNS ,_, approximately_RB 80_CD %_NN of_IN the_DT sheep_NN in_IN each_DT flock_NN could_MD be_VB assessed_VBN ._SENT In_IN this_DT study_NN ,_, the_DT third-eyelid_JJ test_NN identified_VBN PrPSc-positive_JJ sheep_NN in_IN flocks_VBZ with_IN previous_JJ scrapie_NN exposure_NN ,_, although_IN in_IN two_CD cases_NNS the_DT individual_JJ sheep_NN identified_VBN by_IN eyelid_NN biopsy_NN had_VBD no_RB reported_VBN contact_NN with_IN an_DT infected_JJ ewe_NN at_IN parturition_NN ._SENT The_DT efficiency_NN of_IN the_DT programs_NNS (_( 2_CD to_TO 3_CD %_NN in_IN this_DT relatively_RB small_JJ sample_NN )_) exceeds_VBZ the_DT estimated_JJ scrapie_NN prevalence_NN level_NN of_IN 0.07_CD %_NN nationally_RB and_CC illustrates_VBZ the_DT potential_JJ value_NN of_IN preclinical_JJ surveillance_NN ._SENT However_RB ,_, there_EX are_VBP some_DT limitations_NNS to_TO the_DT use_NN of_IN the_DT eyelid_NN test_NN in_IN a_DT scrapie_NN eradication_NN program_NN ._SENT One_CD hundred_CD to_TO 150_CD sheep_NN can_MD be_VB sampled_VBN per_IN day_NN in_IN a_DT single_JJ location_NN with_IN proficient_JJ personnel_NNS using_VBG restraint_NN equipment_NN available_JJ on_IN most_JJS facilities_NNS ;_: testing_VBG small_JJ numbers_NNS of_IN sheep_NN at_IN multiple_JJ locations_NNS decreases_VBZ the_DT efficiency_NN of_IN the_DT testing_NN personnel_NNS ._SENT The_DT costs_NNS of_IN personnel_NNS ,_, equipment_NN ,_, topical_JJ anesthetics_NNS ,_, and_CC sample_NN testing_NN are_VBP borne_VBN by_IN the_DT state_NN and_CC federal_JJ governments_NNS through_IN a_DT joint_JJ scrapie_NN eradication_NN program_NN ._SENT Although_IN the_DT procedure_NN is_VBZ performed_VBN under_IN local_JJ anesthesia_NN ,_, third-eyelid_JJ sampling_NN may_MD be_VB perceived_VBN as_RB objectionable_JJ by_IN some_DT producers_NNS ._SENT The_DT third-eyelid_JJ test_NN is_VBZ most_RBS useful_JJ in_IN animals_NNS between_IN the_DT ages_NNS of_IN 14_CD and_CC 36_CD months_NNS ,_, because_IN older_JJR animals_NNS tend_VBP to_TO have_VB smaller_JJR areas_NNS of_IN lymphoid_JJ tissue_NN ._SENT Further_RBR ,_, the_DT estimated_JJ test_NN sensitivity_NN is_VBZ approximately_RB 85_CD to_TO 90_CD %_NN ._SENT Therefore_RB ,_, the_DT third-eyelid_JJ test_NN is_VBZ not_RB suitable_JJ as_IN a_DT stand-alone_JJ eradication_NN tool_NN ._SENT The_DT test_NN is_VBZ more_RBR appropriately_RB considered_VBN an_DT adjunct_JJ surveillance_NN tool_NN to_TO identify_VB infected_JJ flocks_VBZ which_WDT could_MD then_RB be_VB managed_VBN through_IN an_DT integrated_JJ program_NN of_IN testing_NN ,_, necropsy_NN or_CC quarantine_NN ,_, genetic_JJ selection_NN ,_, and_CC husbandry_NN modifications_NNS ._SENT The_DT test_NN is_VBZ also_RB useful_JJ for_IN identification_NN of_IN naturally_RB infected_JJ sheep_NN for_IN transfer_NN to_TO research_NN facilities_NNS ._SENT Although_IN active_JJ surveillance_NN is_VBZ expensive_JJ ,_, cost-effectiveness_NN is_VBZ increased_VBN by_IN targeting_VBG the_DT testing_NN program_NN to_TO 14-_CD to_TO 24-month-old_JJ sheep_NN of_IN heavily_RB impacted_VBN breeds_NNS in_IN flocks_VBZ with_IN a_DT history_NN of_IN purchasing_VBG breeding_VBG ewes_NNS from_IN multiple_JJ sources_NNS ._SENT Active_JJ surveillance_NN is_VBZ a_DT justifiable_JJ addition_NN to_TO live-animal_JJ passive_JJ surveillance_NN ,_, in_IN which_WDT flocks_VBZ are_VBP identified_VBN only_RB after_IN submission_NN of_IN a_DT clinical_JJ suspect_NN ._SENT One_CD of_IN the_DT sheep_NN quarantined_VBN after_IN selection_NN by_IN this_DT program_NN was_VBD found_VBN dead_RB with_IN no_DT history_NN of_IN clinical_JJ signs_NNS ,_, and_CC another_DT remains_VBZ clinically_RB normal_JJ at_IN the_DT age_NN of_IN 36_CD months_NNS ._SENT Inapparently_RB infected_JJ sheep_NN such_JJ as_IN these_DT produce_NN lambs_VBZ annually_RB and_CC serve_VB as_IN a_DT continuing_VBG source_NN of_IN the_DT transmissible_JJ agent_NN ._SENT Slaughter_NN surveillance_NN and_CC active_JJ live-animal_JJ surveillance_NN programs_NNS such_JJ as_IN the_DT Wyoming_NP pilot_NN program_NN will_MD be_VB critical_JJ for_IN identification_NN of_IN infected_JJ flocks_VBZ and_CC eventual_JJ disease_NN eradication_NN ._SENT This_DT study_NN demonstrated_VBD that_DT identification_NN of_IN scrapie-infected_JJ flocks_VBZ by_IN third-eyelid_JJ testing_NN is_VBZ technically_RB feasible_JJ with_IN proficient_JJ personnel_NNS and_CC adequate_JJ field_NN and_CC laboratory_NN resources_NNS ._SENT Third-eyelid_JJ testing_NN and_CC genotype_NN analysis_NN are_VBP useful_JJ in_IN identifying_VBG infected_JJ flocks_VBZ for_IN regulatory_JJ intervention_NN and_CC infected_JJ animals_NNS suitable_JJ for_IN research_NN purposes_NNS ._SENT Active_JJ surveillance_NN for_IN scrapie_NN is_VBZ a_DT useful_JJ component_NN of_IN an_DT integrated_JJ scrapie_NN control_NN program_NN based_VBN on_IN permanent_JJ identification_NN ,_, flock_NN monitoring_NN ,_, slaughter_NN surveillance_NN ,_, and_CC passive_JJ surveillance_NN by_IN diagnosis_NN of_IN clinical_JJ suspects_NNS with_IN testing_NN of_IN their_PP$ scrapie-exposed_JJ flockmates_NNS ._SENT 